

**AN INVESTIGATION ON THE SERODETECTION
OF DENGUE VIRUS IN SABAH,
MALAYSIAN BORNEO**

ZULINA MAZLAN

**PERPUSTAKAAN
UNIVERSITI MALAYSIA SABAH**

**THESIS SUBMITTED IN FULLFILLMENT FOR THE
DEGREE OF MASTER OF SCIENCE
(MEDICAL SCIENCE)**

**FACULTY OF MEDICINE AND HEALTH SCIENCES
UNIVERSITI MALAYSIA SABAH
2019**



UMS
UNIVERSITI MALAYSIA SABAH

UNIVERSITI MALAYSIA SABAH
BORANG PENGESAHAN STATUS TESIS

JUDUL: **AN INVESTIGATION ON THE SERODETECTION OF DENGUE VIRUS
IN SABAH, MALAYSIAN BORNEO.**

IJAZAH: **SARJANA SAINS (PENGAJIAN SAINS PERUBATAN)**

Saya **ZULINA BINTI MAZLAN**. Sesi **2015-2019** mengaku membenarkan tesis Master ini disimpan di Perpustakaan Universiti Malaysia Sabah dengan syarat-syarat seperti berikut:-

1. Tesis ini adalah hak milik Universiti Malaysia Sabah.
2. Perpustakaan Universiti Malaysia Sabah dibenarkan membuat Salinan untuk tujuan pengajian sahaja.
3. Perpustakaan dibenarkan membuat Salinan tesis ini sebagai bahan pertukaran antara institusi pengajian tinggi.
4. Sila tandakan (/)


SULIT

(Mengandungi maklumat yang berdarjah keselamatan atau kepentingan Malaysia seperti yang termaktub di dalam AKTA RAHSIA 1972)

TERHAD

(Mengandungi maklumat TERHAD yang telah ditentukan oleh organisasi/badan di mana penyelidikan dijalankan)

TIDAK TERHAD



ZULINA MAZLAN
MM1511012T

Tarikh: 11 April 2019

Disahkan Oleh,
NORAZLYNN MOHD. JOHAN @ JAHYNA

PUSTAKAWAN
UNIVERSITI MALAYSIA SABAH

(Tandatangan Perpustakawan)


DR. MOHAMMAD ZAHLIRUL HOQUE
Associate Professor
Faculty Of Medicine & Health Sciences
University Malaysia Sabah
MURIAH


(Prof. Madya Dr. Mohammad Zahirul Hoque) 3636

Penyelia


(Prof. Dr. Helen Benedict Lasimbing) BENEDICT LASIMBING
Penyelia Bersekutif
Hospital Universiti Malaysia Sabah
Fakulti Perubatan dan Sains Kesihatan
No. Pendaftaran MPM: 29703


(Prof. Madya Dr. Vijay Kumar Subbiah)

Penyelia Bersama
PROF. MADYA DR. VIJAY KUMAR
PROFESOR MADYA

INSTITUT PENYELEDIKAN & TEKNOLOGI

UNIVERSITI MALAYSIA SABAH



UMS
UNIVERSITI MALAYSIA SABAH

**PERPUSTAKAAN
UNIVERSITI MALAYSIA SABAH**

DECLARATION

I hereby declare that the material in this thesis is my own except for quotation, excerpts, equation, summaries and references, which have been duly acknowledged.

Date: 24 July 2018



Zulina Binti Mazlan
MM1511012T



CERTIFICATION

NAME : ZULINA BINTI MAZLAN
MATRIC NO : MM1511012T
**DEGREE : AN INVESTIGATION ON THE
SERODETECTION OF DENGUE VIRUS IN
SABAH, MALAYSIAN BORNEO.**

DEGREE : MASTER OF SCIENCE (MEDICAL SCIENCE)

VIVA DATE : 17 JANUARY 2019

CERTIFIED BY

1. SUPERVISOR


Assoc. Prof. Dr. Mohammad Zahirul Hoque

Signature

DR MOHAMMAD ZAHIRUL HOQUE
Associate Professor
Faculty of Medicine & Health Sciences
University Malaysia Sabah
Malaysia
MMC FULL Reg. No.53636


2. CO-SUPERVISOR

Prof. Dr. Helen Benedict Lasimbang


PROF. DR HELEN BENEDICT LASIMBANG
Ketua Pegawai Eksekutif
Hospital Universiti Malaysia Sabah
Fakulti Perubatan dan Sains Kesihatan
No. Pendaftaran MPM: 29703


3. CO-SUPERVISOR

Assoc. Prof. Dr. Vijay Kumar Subbiah


PROF. MADYA DR. VIJAY KUMAR
PROFESOR MADYA
INSTITUT PENYELIDIKAN P'TEKNOLOGI
UNIVERSITI MALAYSIA SABAH




ACKNOWLEDGEMENT

I would first and foremost like to thanks almighty Allah Taala, who has given me the strength and blessing to complete my thesis despite the obstacles I faced to reach it. My sincere gratitude to Universiti Malaysia Sabah (UMS) for providing the study grant and Pathology Department, Sabah Women and Child Hospital, Pathology Department, Hospital Tuaran and also Sabah Regional Blood Centre for providing me the samples, and facility to carried out my study.

This dissertation is dedicated to my father Mr. Mazlan Bin Hashim who motivate me the important of education, dedication, and hark work and my mother Mrs. Hazizah Binti Yaacob who inspiring, loving, and encouraging throught my life and lastly to my beloved husband Mr. Azlam Bin Abdul Rahman and my three beautiful childrens Miss. Airish Aleesya Binti Azlam, Miss Asfa Erynna Binti Azlam and Mr. Muhammad Hakeem Ar Rayyan Bin Azlam as my pillar of strength and share all the up and down to finish my study and complete this dissertation.

I would like to express my deepest gratitude to AP. Dr. Mohammad Zahirul Hoque, my supervisor for his instructions, guidance, encouragement, valuable suggestions, and support throughout my study. I deeply appreciate the time he spared me during the preparation of this study. I wish to express my sincere appreciation to Ap Dr. Helen Benedict Lasimbang and AP. Dr. Vijay Kumar, my co-supervisor for the kindness, help and constructive comments. I especially want to thanks to the Dean, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah. I would like to thanks Pathology and Transfusion Medicine Department, SWACH, Pathology Department, Hospital Tuaran for their great help in this study.

Sincere thanks to my brother Mr. Zulkarnain, and all my lovely sisters Zulaikha, Norailiza, Noor Aida and Nor Nazira, nephew and niece for always standing by me and keep me motivated through difficult times.

Zulina Binti Mazlan
24 July 2018



ABSTRACT

Background: Dengue is re-emerging mosquito-borne infection and one of significant public health concern and has been expanding its distribution in a various part of the world. Dengue cases were more common in tropical and subtropical regions of the world. Dengue infection is endemic disease and can be transmitted by blood transfusion. Malaysia is one of the severe dengue-endemic country in Southeast Asia with the presence of all four serotypes (DENV1, DENV2, DENV3, DENV3, DENV4). Secondary infection of DENV infection by different DENV serotype from primary infection increase the risk for DHF and DSS and mostly related to antibody dependent enhancement (ADE) and transfusion of blood or blood product is one of the dengue treatments increase the blood transfusion safety measured. Periodically seroprevalence study can be used to understand the real burden of dengue in Malaysia population since many cases of dengue is unreported and the total cases of dengue don't reflect the actual dengue situation burden in the population and also marking the readiness of Sabah population for dengue vaccine implementation according to WHO recommendation. The objective of the study is to determine the rate of dengue seroprevalence among healthy adult's population from Sabah, Malaysia. **Methods:** A prospective cross-sectional study was conducted on blood donor samples from December 2016 to August 2017. This research was approved by the Medical Research & Ethics Committee (MREC), Ministry of Health, Malaysia and Research and Ethical Committee University Malaysia Sabah. Serum samples from 364 eligible blood donors were collected from Sabah Women and Children Hospital (SWACH) age 18-65 years and examined for the presence of dengue-specific immunoglobulins G (IgG) using enzyme-linked immunosorbent assay (ELISA) according to manufacturer's protocol. The ABO group of the blood donor were identified by agglutination test according to manufacturer protocol. Data were entered and statistically analyzed by SPSS, Version 24 (IBM) for gender, age, ethnicity, localities area, blood grouping and the results of dengue IgG. **Results:** Majority of the resident having previous dengue infection belong to the age group of 18 to 65 years was 36.5% (N=133, 95% Confidence interval [CI] = 0.059-0.117%). Dengue antibodies IgG prevalence increased with age with the lowest in 18-26 years age group (30.5%) and the highest in 56-65 years age group (73.3%). There are no significant differences for dengue seroprevalence seen when compare according to gender, localities, ethnicity and blood group. **Conclusions:** This result shows the high prevalence of dengue antibodies among Sabah blood donor. High-prevalence of Dengue IgG seropositivity reflects the high endemicity of dengue disease in this region of Malaysia. This finding also alerts the authorities to reconsider on adding the dengue screening in the blood screening panel for blood product to reduce the ADE risk. DENV seroprevalence among Sabah population were rather low for dengue vaccine implementation according to WHO recommendation in 2017.

Key Words: Dengue fever, seroprevalence, blood donor, Sabah

ABSTRAK

KAJIAN SEROLOGI BAGI MENGESAN KEHADIRAN VIRUS DENGGI DI SABAH, MALAYSIA BORNEO

Latar belakang: Demam denggi adalah penyakit bawaan nyamuk yang kembali menyerang kebanyakan negara di seluruh dunia dan merupakan penyakit berjangkit yang memberi impak negatif terhadap kesihatan sejagat. Kes demam denggi biasanya dilaporkan di kawasan tropika dan subtropika di dunia. Jangkitan denggi adalah penyakit endemik dan boleh disebarluaskan melalui pemindahan darah. Malaysia adalah salah satu daripada negara-negara endemik denggi di Asia Tenggara dengan kesemua serotype virus denggi dikesan ada di Malaysia. Pesakit yang mempunyai antibodi terhadap virus denggi hasil daripada jangkitan pertama boleh menyumbang kepada peningkatan risiko kematian dalam jangkitan sekunder demam denggi dengan serotype berlainan. Kajian serologi bagi mengesan antibodi terhadap virus denggi secara berkala dapat digunakan untuk memahami beban sebenar penyakit denggi di kalangan penduduk di Malaysia kerana kebanyakan kes denggi tidak dilaporkan dan jumlah kes denggi yang dilaporkan tidak mencerminkan beban penyakit denggi sebenar dalam populasi di Malaysia. Objektif kajian ini adalah untuk mengkaji sejauh mana magnitud jangkitan virus denggi di kalangan penduduk dewasa yang sihat di Sabah. **Metodologi:** Kajian ini dijalankan ke atas sampel penderma darah di Hospital Wanita & Kanak-Kanak Sabah selama dua bulan dari bulan Disember 2016 hingga Ogos 2017. Kajian ini telah diluluskan oleh Jawatankuasa Penyelidikan & Etika Perubatan (MREC), Kementerian Kesihatan Malaysia dan Jawatankuasa Penyelidikan dan Etika Universiti Malaysia Sabah. Sampel serum dari 364 penderma darah berusia diantara 18 hingga 65 tahun yang layak dikumpulkan dan disaring bagi mengesan kehadiran imunoglobulin G (IgG) yang khusus terhadap virus denggi menggunakan enzim berkaitan imuno-serapan asai (ELISA) mengikut protokol yang ditetapkan oleh pihak pengeluar. Statistik bagi umur, jantina dan kelaziman antibodi terhadap virus denggi dianalisa menggunakan perisian SPSS, Versi 24 (IBM) untuk umur, jantina dan keputusan IgG denggi. **Keputusan:** Majoriti penduduk yang pernah dijangkiti demam denggi yang berumur 18 hingga 65 tahun adalah 36.5% ($N = 133$, 95% selang Keyakinan [CI] = 0.059-0.117%). Antibodi IgG terhadap virus denggi meningkat selari dengan kenaikan umur penduduk dimana peratusan terendah dipantau dalam kumpulan umur 18-25 tahun (30.5%) dan tertinggi adalah di kalangan penduduk yang berumur 56-65 tahun (73.3%). **Kesimpulan:** Hasil kajian ini menunjukkan bahawa kelaziman antibodi virus denggi yang tinggi di kalangan penderma darah Sabah. Peratusan yang tinggi terhadap kelaziman antibodi terhadap virus denggi adalah seiring dengan laporan kes demam denggi yang tinggi di rantau ini di Malaysia. Tahap pendedahan kepada jangkitan demam denggi di kalangan generasi muda dilihat masih rendah walaupun terdapat episod wabak denggi yang dilaporkan di Sabah. Penduduk Sabah terutamanya generasi muda adalah berisiko mengalami wabak denggi yang magnitude yang lebih tinggi berbanding wabak sebelumnya.

Kata kunci: demam denggi, kelaziman antibodi virus denggi, penderma darah, Sabah.

LIST OF CONTENTS

TITLE	PAGE
DECLARATION	ii
CERTIFICATION	iii
AKNOWLEDGMENT	iv
ABSTRACT	v
ABSTARK	vi
LIST OF CONTENTS	vii
LIST OF TABLES	xiii
LIST OF FIGURES	xiv
LIST OF ABBREBIATION	xviii
LIST OF APPENDICES	xxi

CHAPTER 1: INTRODUCTION

1.1 Background of the study	1
1.2 Research Significant	4
1.3 Research Questions	5
1.4 Research Hypothesis	5
1.4.1 Null Hypothesis	5
1.4.2 Alternate Hypothesis	5
1.5 Research Objective	5
1.5.1 General Objective	5
1.5.2 Specific Objective	6
1.6 Rational of study	6

CHAPTER 2: LITERATURE REVIEWS

2.1 Arbovirus	7
2.1.1 Arbovirus and its Vector	8
2.1.1.1 <i>Culex</i> species	8
2.1.1.2 <i>Aedes</i> species	10
2.2 Dengue	11
2.2.1 Dengue epidemiology worldwide	11



2.2.2	Dengue Epidemiological Finding in Asia	13
2.2.3	Dengue Epidemiological finding in Malaysia	13
2.2.4	Dengue Epidemiology in Sabah	17
2.2.5	Dengue Seroepidemiology in Malaysia	19
2.2.6	Dengue Virus	21
2.2.7	Dengue Virus Structure	22
	2.2.7.1 Dengue Envelope	22
	2.2.7.2 Dengue Virus Capsid	23
2.2.8	Clinical feature of DENV infection	23
2.2.9	Host Immune respond towards dengue infection	27
2.2.10	Dengue virus transmission	28
	2.2.10.1 Dengue virus transmission via mosquito's vector	28
	2.2.10.2 DENV Transmission through blood transfusion and Blood transfusion safety	29
2.2.11	The prevailing view of increasing dengue cases	30
2.2.12	Dengue virus infection control and prevention	32
	2.2.12.1 DENV primary vector control strategies	32
	2.2.12.2 Future DENV Vaccine implementation strategies	33
2.2.13	Dengue seroprevalence studies	34
	2.2.13.1 Seroprevalence contributed to better understanding of DENV burden and disease severity	36
	2.2.13.2 The relationship between seroprevalence Of DENV antibody and DENV vaccine implementation	37
	2.2.13.3 The dengue seroprevalence among blood donor triggers the transfusion safety awareness	38
2.2.14	Dengue seroprevalence in Malaysia	40



2.2.15	Dengue Diagnostic Testing	41
2.2.15.1	Rapid Dengue NS1 Antigen detection (Membrane-based immunoassay)	45
2.2.15.2	Dengue IgG & IgM Antibodies Detection	46
2.2.15.2.1	Rapid Dengue IgG & IgM Antibodies Detection (Membrane-based immunoassay)	49
2.2.15.2.2	Dengue Antibody IgM ELISA Assay	50
2.2.15.2.3	Dengue Antibody IgG ELISA Assay	51
2.2.15.2.4	Molecular diagnostic of Dengue (Real-Time Polymerase Chain Reaction)	54
3.0	CHAPTER 3: METHODOLOGY	55
3.1	Ethics Statement	55
3.2	Study Design	55
3.3	Study area and subject	56
3.4	Subject inclusion and exclusion criteria	57
3.4.1	Inclusion criteria	57
3.4.2	Exclusion criteria	58
3.5	Sample Size calculation (n)	58
3.6	Personal Information Form	59
3.7	Laboratory tests	59
3.7.1	Specimen Collection and Preparation	59
3.7.2	Serum predilution	59
3.7.3	Assay Plate procedure	61
3.7.4	Panbio Unit Calculation from the absorbance value	62
3.7.5	Interpretation of Results	62
3.7.6	ABO Grouping Test	63
3.7.6.1	Specimen collection and preparation	63

3.7.6.2	ABO Grouping testing	63
3.7.6.3	ABO Grouping results interpretation	64
3.7.7	Statistical analysis	65
3.7.7.1	The distribution for general characteristic of study subject (gender, age group, ethnicity, localities)	65
3.7.7.2	General prevalence of anti-DENV IgG among all study group	65
4.0	CHAPTER 4: RESULTS	67
4.1	Introduction	67
4.2	General Characteristic of The Study Group	67
4.2.1	The distribution of the study group by gender	68
4.2.2	The distribution of the study group by age categories	68
4.2.3	The distribution of the study group by ethnicity	69
4.2.4	The distribution of the study group by localities	70
4.2.5	The distribution of the study group by blood group ABO	70
4.3	General prevalence of anti-DENV IgG among all study group	72
4.3.1	Prevalence, Odds Ratio (OR) and P value of anti-DENV IgG by gender	72
4.3.2	Prevalence, Odds Ratio (OR) and P value of anti-DENV IgG by age categories	72
4.3.3	Prevalence, Odds Ratio (OR) and P value of anti-DENV IgG by ethnicity	74
4.3.4	Prevalence, Odds Ratio (OR) and P value of anti-DENV IgG by localities	76
4.3.5	Prevalence, Odds Ratio (OR) and P value of anti-DENV IgG by blood group ABO	77
4.4	Characterization the dengue seroprevalence determined in this study to other dengue seroprevalence done in West Malaysia, Southeast Asia and other countries.	79

4.4.1	Characterization the dengue seroprevalence determined in this study to other studies of dengue seroprevalence done in Malaysia	79
4.4.2	Characterization the dengue seroprevalence determined in this study to other studies of dengue seroprevalence done in Southeast Asia	80
4.4.3	Characterization the dengue seroprevalence determined in this study to other studies of dengue seroprevalence done in others countries	81
4.5	Characterization the dengue seroprevalence determined in this study with other dengue seroprevalence study that involved the blood donor as the study subject.	82
5.0	CHAPTER 5: DISCUSSION	84
5.1	Introduction	84
5.2	Discussion of the results	85
5.2.1	Study site & participant	85
5.2.2	General Characteristic of the study group	86
5.2.2.1	The distribution of study group by gender	86
5.2.2.2	The distribution of study group by age categories	86
5.2.2.3	The distribution of study group by ethnicity	86
5.2.2.4	The distribution of study group by localities	87
5.2.2.5	The distribution of study group by ABO blood group	87
5.2.3	General prevalence of anti-DENV IgG among all study group	88
5.2.3.1	Prevalence, Odd ratio (OR) and the P value of the anti-DENV by gender.	89
5.2.3.2	Prevalence, Odd ratio (OR) and the P value of the anti-DENV by age group.	89
5.2.3.3	Prevalence, Odd ratio (OR) and the	90



	P value of the anti-DENV by ethnicity.	
5.2.3.4	Prevalence, Odd ratio (OR) and the P value of the anti-DENV by localities.	91
	P value of the anti-DENV by ABO blood group.	
5.3	Characterization the dengue seroprevalence determined in this study to other dengue seroprevalence done in West Malaysia, Southeast Asia and other countries	93
5.3.1	Characterization the dengue seroprevalence determined in this study to other studies of dengue seroprevalence done in Malaysia	94
5.3.2	Characterization the dengue seroprevalence determined in this study to other studies of dengue seroprevalence done in Southeast Asia	94
5.3.3	Characterization the dengue seroprevalence determined in this study to other studies of dengue seroprevalence done in others countries	94
5.4	Characterization the dengue seroprevalence determined in this study with other dengue seroprevalence study that involved the blood donor as the study subject and the blood transfusion safety.	95
5.5	Dengue seroprevalence and the Sabah region readiness for the dengue vaccination implementation	95
5.6	Study Limitation	97
6.0	CHAPTER 6: CONCLUSION	
6.1	Conclusion	98
6.2	Future commendations	99
REFERENCES		100
APPENDICES		108

LIST OF TABLES

	Page	
Table 2.1	The list of dengue seroprevalence study done in the recent decade worldwide.	34
Table 2.2	The dengue seroprevalence indicated the feasibility introduction of DENV Vaccine as recommended by WHO.	38
Table 3.1	Results and results interpretation elaborated from the Index Value or Panbio Units calculated from the absorbance value read using spectrophotometer at wavelength 450nm with reference filter 650nm	62
Table 3.2	The results interpretation, possibility and suggestion	63
Table 3.3	The reaction pattern of the common ABO phenotyping. The positive (+) results indicated that the hemagglutination seen in the respective test tube for each monoclonal antibody tested. The negative (-) results indicated there no hemagglutinations seen in the specific monoclonal antibody tested.	64
Table 4.1	Distribution of dengue seroprevalence among the participants according to their gender (n = 364).	72
Table 4.2	Distribution of dengue seroprevalence among the participants according to their age categories (n = 364).	74
Table 4.3	Distribution of dengue seroprevalence among the participants according to their ethnicity (n = 363) and 1 study subject were excluded due to difference nationality.	75
Table 4.4	Distribution of dengue seroprevalence among the participants according to their localities (n = 364).	77
Table 4.5	Distribution of dengue seroprevalence among the participants according to their blood group ABO (n = 364).	78

LIST OF FIGURES

	Page
Figure 2.1 The classification of Arbovirus	7
Figure 2.2 The image of Culex spp, the mosquito with the faint white band with white stripes along the legs and dark chevrons on the abdomen	8
Figure 2.3 Aedes aegypti female mosquitos were feeding blood using its proboscis from human skin	10
Figure 2.4 "Dengue Belt" World regions that infected by Dengue virus as reported by WHO in 2013	12
Figure 2.5 Dengue cases reported in Malaysia from 1973 to 1992	14
Figure 2.6 Reported dengue cases in Malaysia from 1995 to September 2017. A total number of cases yearly shows in (blue bars), and values are shown on top of the bars. An orange line shows total mortality cases.	15
Figure 2.7 The dengue cases trend by weekly for 2016 vs. 2017, there are relatively decreasing in dengue cases reported from January to March 2017 and August to December 2017 compared to the same period on 2016.	17
Figure 2.8 Dengue cases distribution for Sabah State from 2015 to August 2017. Source Sabah State Epid Bulletin week 33, Access date 25 September 2017	19
Figure 2.9 The structure of the DENV, envelope coating the lipid bilayer membrane protected the capsid that consists of the virus genome.	22
Figure 2.10 Dengue Fever Flowchart	24
Figure 2.11 DHF phase of infection	26
Figure 2.12 The Host immune respond toward dengue infection started from the bite of infected Aedes aegypti	27
Figure 2.13 Age-specific seroprevalence of dengue observed between 2000 and 2013	41
Figure 2.14 Subsequent phase of dengue infection, starting day 1 of fever consist with viremia and NS1 detection. Body starts	44



	to produce anti-DENV IgG and anti-DENV IgM since onset but reach detected level on day 3 for anti-DENV IgG and day 5 for anti-DENV IgM. Anti-DENV IgM remains detected until 2 to 3 months, and anti-DENV IgG will remain detected for life	
Figure 2.15	The difference in secondary infection compares to primary infection where the early rise of anti-DENV IgG nearly 4-fold compared to primary infection. Anti-DENV IgM rise but much lower titer and remains on few days in blood circulation during secondary infection	46
Figure 2.16	The Rapid Dengue NS1 Antigen Detection Kit used by HWKKS. The Kits Sensitivity is 92.9% while the specificity is 98.7%	47
Figure 2.17	The cassette showed a visible line appears on test Line (T) indicate positive results	48
Figure 2.18	Rapid dengue IgM/IgG that been used by SWACH as a screening tool for detection of anti-DENV IgM and Anti-DENV IgG in suspected DENV patient	50
Figure 2.19	The Indirect ELISA reaction inside the microwells. 1) Microwells was precoated with the dengue antigen (1,2,3,4). 2) Anti-DENV IgG from the subject sera was bind to the coated antigen. 3) HRP Conjugated was bind to the antigen-antibody DENV IgG complex. 4) TMB substrate was added and the reaction started inside the microwells and developed the blue colour. 5) The stop solution was added after allow the TMB substrate reaction incubation period of 10 minutes to stop the reaction and the blue colour change to yellow colour. The microwells was ready to be read within 30 minutes to avoided any false reaction	53
Figure 3.1	Medical officer give consultation to donor candidate and take the eligible donor consensus to participate in this study	56



Figure 3.2	Blood mobile drive campaign by Transfusion Medicine Unit, SWACH	57
Figure 3.3	Flow Chart of Dengue Indirect IgG ELISA followed manufacturer instruction	61
Figure 4.1	The Distribution of the study subjects by gender	68
Figure 4.2	The distribution of the study subject by age categories.	69
Figure 4.3	The distribution of the study subjects by ethnicity	69
Figure 4.4	The distribution of the study subjects by locality Urban (Kota Kinabalu, Sandakan, Tawau), Rural (all other district), Outside Sabah (Labuan & Sarawak).	70
Figure 4.5	The distribution of the study subject by blood grouping	71
Figure 4.6	Prevalence of dengue seroprevalence based on the anti-DENV IgG test among blood donors who participated in the study (n = 364).	71
Figure 4.7	Age-dependent distribution of dengue seroprevalence among the participants (n = 364) based on the anti-DENV IgG test. The blue line shows the dengue seroprevalence were increasing with the increasing of age.	73
Figure 4.8	Ethnicity-dependent distribution of dengue seroprevalence among the participants (n = 363) based on the anti-DENV IgG test.	75
Figure 4.9	Locality-dependent distribution of dengue seroprevalence among the participants (n = 364) based on the anti-DENV IgG test. Urban (Kota Kinabalu, Sandakan and Tawau), Rural others district in Sabah and Outside Sabah (Labuan and Sarawak)	76
Figure 4.10	Blood Grouping-dependent distribution of dengue seroprevalence among the participants (n = 364) based on the anti-DENV IgG test.	78
Figure 4.11	The seroprevalence of anti-DENV IgG determined in this study was compared to dengue seroprevalence studies reported in Malaysia from 2001 to 2018. NPHL*-7 primary care clinics all located at city areas in different states of	80

	Selangor, Wilayah Persekutuan Kuala Lumpur, Perak, Kelantan, Johor and Sabah, TMC- The Malaysian Cohort Study (Chew <i>et al</i> , 2012),	
Figure 4.12	The seroprevalence of anti-DENV IgG determined in this study was compared to dengue seroprevalence studies reported in Southeast Asia from 2009 to 2017.	81
Figure 4.13	The seroprevalence of anti-DENV IgG determined in this study was compared to studies reported in Southeast Asia from 2009 to 2017.	82
Figure 4.13	The seroprevalence of anti-DENV IgG determined in this study was compared to dengue seroprevalence studies involved the blood donor population in Malaysia, Singapore, Saudi Arabia and India.	83

LIST OF ABBREVIATION

WHO	- World Health Organization
NTDs	- Neglected Tropical Disease Strategy
RNA	- Ribonucleic Acid
DENV	- Dengue virus
DENV1	- Dengue serotype 1
DENV2	- Dengue serotype 2
DENV3	- Dengue serotype 3
DENV4	- Dengue serotype 4
MOH	- Ministry of Health
CPG	- Clinical Practice Guideline
WSN	- West Nile Virus
YF	- Yellow Fever Virus
CHKV	- Chikungunya Virus
RVF	- Rift Valley Fever
JE	- Japanese encephalitis
CDC	- Clinical Diagnosis Centre
ZIKV	- Zika Virus
DF	- Dengue Fever
DHF	- Dengue Hemorrhagic Fever
DSS	- Dengue Shock Syndrome
SPWD	- Dengue Epidemic Management System
DENV5	- Dengue serotype 5
nm	- Nano meter
kDa	- Kilo Dalton
E	- Envelope
C	- Capsid
prM	- Pre-Membrane
NS1	- Non-Structural Protein 1
IFN	- Interferon
ER	- Endoplasmic Reticulum
TGN	- Trans-Golgi Network
CD8	- Cluster of Differentiation



HIV	- Human Immunodeficiency Virus
HCV	- Hepatitis C Virus
IgG	- Immunoglobulin G
Anti-DENV	- Dengue antibody
GIS	- Geographic Information System
STI	- Sterile insert technique
IGRS	- Insect Growth Regulators
ADE	- Antibody Dependent Enhancement
CYD-TDV	- Dengue Vaccine Candidate
SAGE	- Strategic Advisory Groups of Expert
Fcy	- Receptor protein on White Blood Cells
ELISA	- Enzymatic Line
RT-PCR	- Real Time Polymerase Chain Reaction
sNS1	- Secreted NS1
SWACH	- Sabah Women and Children Hospital
IgM	- Immunoglobulin M
HRP	- Horseradish peroxidase
TMB	- Tetramethylbenzidine
OD	- Optical Density
HI	- Hemagglutination Inhibition Test
NMRR	- National Medical Research Register
'N	- North
'E	- East
°C	- Degree Celsius
HBV	- Hepatitis B Virus
G6PD	- Glucose-6 Phosphate Dehydrogenase
n	- Number
Za	- Standard Normal Deviate
P	- Prevalence Rate
ml	- Milliliter
N	- Negative Control
R	- Reactive Control
CAL	- Calibrator
uL	- Microliter



SPSS	- SPSS
CI	- Confident Interval
%	- Percentage
RBC	- Red Blood Cell
>	- More than

LIST OF APPENDICIES

		Page
APPENDIX A	Approval Ethical by Medical Research Ethics Committee	108
APPENDIX B	Approval NMRR Ethical	109
APPENDIX C	Subject Information and Informed Consent Form	110
APPENDIX D	Photograph of Research Study	114
APPENDIX E	Certificate of Participation as Poster Presentation	117



CHAPTER 1

INTRODUCTION

1.1 Background of the study

Dengue fever is a major public health concern with more and more cases reported worldwide. Dengue and severe dengue are listed as one of the 17 diseases in the World Health Organization (WHO) "Accelerating Work to Overcomes the Global Impact of Neglected Tropical Diseases (NTDs)" launched in 2012. The aimed to overcome the global impact of the neglected tropical disease (NTDs) so the diseases can be controlled more effectively and in many cases the disease can be eliminated and the ultimate goal to eradicated the disease with nearly half of the worldwide population living in risk area (WHO, 2012). There are five strategies suggested by WHO to achieved the goal against these 17 diseases worldwide. For Dengue and severe dengue diseases, WHO as put a target to focus on sustained the dengue vector by established the vector control interventions in 10 priorities country by 2015. Furthermore, WHO aim to established the dengue control and surveillance system in all region by 2020. The Dengue cases was targeted to be reduce more than 25% compare to 2009-2010 dengue cases (base line) and the mortality cases reduce at least 50% by 2020 (WHO, 2012).

The Dengue virus is a single-stranded positive RNA virus with lipid-envelope, small and under the genus *Flavivirus*, family *Flaviviridae*. Sequence variation of 30-35% allows DENV to be grouped into four known serotypes (DENV1, DENV2, DENV3, and DENV4) and each is capable of causing the entire range of dengue-related disease symptoms (de-Azeredo *et al.*, 2015, Velasco-Salas *et al.*, 2014). Fifth dengue serotype has been found in Sarawak in 2013 although this claim is still controversial (Dejnirattisai *et al.*, 2010, Mustafa *et al.*, 2015). Dengue infection is reported to thrive in poor urban area in the tropic and subtropical region.



The worldwide map of dengue distribution worldwide was seen dramatic changes when Singapore and Japan reported the sudden increase in dengue cases after a decade of silence (Pang *et al.*, 2016). Many studies have concluded that dengue infection has been invaded in a variable region involve various geographic covering urban or rural area. The abilities of mosquitos *Aedes aegypti* and *Aedes albopictus* well-known as most prolific dengue vector strive that adapted well in a rapidly changing related to urban environment. These special abilities can be one of the factors that contribute dengue cases remain increasing trends throughout the years (de-Azeredo *et al.*, 2015).

Dengue Cases has dramatically increased worldwide including Malaysia from 2012 (21,900) until 2015 (120,836) up to 551%-fold (Tauqueer *et al.*, 2017). WHO reported the current worldwide Dengue burden is 2.5 billion infected people in more than 125 countries with approximately 20,000 mortality cases per year (Ayukekpong *et al.*, 2014, Mahmood *et al.*, 2013). Increasing urbanization in various part of the world, a leak of personal protection again mosquito, increasing factor that promoting the mosquitoes breading site and the changes of meteorological with high rainfall, humidity, and temperature related to global warming (Pang *et al.*, 2016). Another factor that contributes to increasing of dengue infection is the potential role of the foreign visitor who arrives in this region from Asian countries with known dengue endemic (Ashshi *et al.*, 2017).

The sudden increase in dengue cases can also be attributed to the east access online data collection and reporting. However, dengue cases are generally considered as under-reported, misdiagnosed as there are many patients who do not seek treatment in the government facilities such as hospital or primary care outpatient clinic (Higa *et al.*, 2011). Dengue symptoms can be similar to other viruses (Mahmood *et al.*, 2013). There are also possibilities may be other possibilities that patients may seek medical attention from private health facilities and hence the cases were not captured and included in WHO dengue statistic (Ng *et al.*, 2015). WHO reported in 2015, 70% of the world population are exposed to the risk of dengue infection live in the Asia Pacific regions (Bhatt *et al.*, 2013, WHO, 2017).

REFERENCES

- Mohd Zim, A., M., I. C. Sam, Sharifah Omar, Yoke-Fun Chan, Sazaly Abu Bakar and Adeeba Kamarulzaman. 2012. *Chikungunya Infection in Malaysia: Comparison with Dengue Infection in Adults and Predictors of Persistent Arthralgia*, Vol. 56.
- AbuBakar, Sazaly, Pooi-Fong Wong and Yoke-Fun Chan. 2002. "Emergence of Dengue Virus Type 4 Genotype Iia in Malaysia." *Journal of General Virology* 83:2437-42.
- Abu Bakar S, Lim Y. 2011. "Urbanization and the spread of the dengue to rural populationin Malaysia". (Abstract 11.095). International Society for Infectious Diseases-Neglected Tropical Disease 2011 meeting: 2011 Boston: International Society for Infectious Diseases; 2011
- Alen, M. M. and D. Schols. 2012. "Dengue Virus Entry as Target for Antiviral Therapy." *J Trop Med* 2012:628475. doi: 10.1155/2012/628475.
- Ang, L. W., J. Cutter, L. James and K. T. Goh. 2015. "Seroepidemiology of Dengue Virus Infection in the Adult Population in Tropical Singapore." *Epidemiol Infect* 143(8):1585-93. doi: 10.1017/S0950268814002507.
- Ashshi, A. M., S. Alghamdi, A. G. El-Shemi, S. Almdani, B. Refaat, A. M. Mohamed, H. O. Ghazi, E. I. Azhar and F. A. Al-Allaf. 2017. "Seroprevalence of Asymptomatic Dengue Virus Infection and Its Antibodies among Healthy/Eligible Saudi Blood Donors: Findings from Holy Makkah City." *Virology (Auckl)* 8:1-5. doi: 10.1177/1178122X17691261.
- Ayukekbong, James Ayukepi. December 2014. "Dengue Virus in Nigeria: Current Status and Future Perspective." *British Journal of Virology* 1(4):106.
- Barniol, Judit, Roger Gaczkowski, Eliana Vega Barbato, Rivaldo V. da Cunha, Doris Salgado, Eric Martínez, Carmita Soria Segarra, Ernesto B. Pleites Sandoval, Ajay Mishra, Ida Safitri Laksono, Lucy C. S. Lum, José G. Martínez, Andrea Núñez, Angel Balsameda, Ivan Allende, Gladys Ramírez, Efren Dimaano, Kay Thomacheck, Naeema A. Akbar, Eng E. Ooi, Elci Villegas, Tran T. Hien, Jeremy Farrar, Olaf Horstick, Axel Kroeger and Thomas Jaenisch. 2011. "Usefulness and Applicability of the Revised Dengue Case Classification by Disease: Multi-Centre Study in 18 Countries." *BMC Infect Dis* 11(1):106. doi: 10.1186/1471-2334-11-106.
- Bhatt, S., P. W. Gething, O. J. Brady, J. P. Messina, A. W. Farlow, C. L. Moyes, J. M. Drake, J. S. Brownstein, A. G. Hoen and O. Sankoh. 2013. "The Global Distribution and Burden of Dengue." *Nature* 496. doi: 10.1038/nature12060.
- Byk, L. A. and A. V. Gamarnik. 2016. "Properties and Functions of the Dengue Virus Capsid Protein." *Annu Rev Virol* 3(1):263-81. doi: 10.1146/annurev-virology-110615-042334.



- Carrington, L. B. and C. P. Simmons. 2014. "Human to Mosquito Transmission of Dengue Viruses." *Front Immunol* 5:290. doi: 10.3389/fimmu.2014.00290.
- Chaterji, S., J. C. Allen, Jr., A. Chow, Y. S. Leo and E. E. Ooi. 2011. "Evaluation of the Ns1 Rapid Test and the Who Dengue Classification Schemes for Use as Bedside Diagnosis of Acute Dengue Fever in Adults." *Am J Trop Med Hyg* 84(2):224-8. doi: 10.4269/ajtmh.2011.10-0316.
- Chen, Lin H. and Mary E. Wilson. 2004. "Transmission of Dengue Virus without a Mosquito Vector: Nosocomial Mucocutaneous Transmission and Other Routes of Transmission." *Clinical Infectious Diseases* 39(6):e56-e60. doi: 10.1086/423807.
- Cheng WS, Wong GH, Gilleken L. 2003. "Dengue Antibodies in a Sunurban Community in Malaysia." *Med J Malaysia* 58(142-143).
- Chew, Cheng Hoon, Yuan Liang Woon, Faridah Amin, Tassha H. Adnan, Asmah Hani Abdul Wahab, Zul Edzhar Ahmad, Mohd Adam Bujang, Abdul Muneer Abdul Hamid, Rahman Jamal, Wei Seng Chen, Chee Peng Hor, Lena Yeap, Ling Ping Hoo, Pik Pin Goh and Teck Onn Lim. 2016. "Rural-Urban Comparisons of Dengue Seroprevalence in Malaysia." *BMC Public Health* 16(1):824. doi: 10.1186/s12889-016-3496-9.
- Cheah W. K., MRCP*, K S Ng, MRCP**, Abd-Rahman Marzilawati, MMed**, Lucy C S Lum, MRCP**. 2014. "A Review of Dengue Research in Malaysia." *Med J Malaysia* Vol 69 Supplement A(August 2014):9.
- Chow Vincent T.K., C.S. Lim, M.C. Phoon and H.C. Tan. 2005. "A Seroprevalence Survey of Dengue Virus Infection in Healthy Singapore University Undergraduates by Enzyme Immunoassay and Plaque Reduction Neutralization Test." *Dengue Bulletin* 29
- Chew, M. H., M. M. Rahman and S. Hussin. 2015. "Molecular Epidemiology and Phylogenetic Analysis of Dengue Virus Type-1 and 2 Isolated in Malaysia." *Pak J Med Sci* 31(3):615-20. doi: 10.12669/pjms.313.6340.
- Chien, Y. W., Y. C. Shu, K. T. Chuang, C. Y. Yeh, W. C. Ko, N. Y. Ko and G. C. Perng. 2017. "High Estimated Prevalence of Asymptomatic Dengue Viremia in Blood Donors During a Dengue Epidemic in Southern Taiwan, 2015." *Transfusion* 57(11):2649-56. doi: 10.1111/trf.14281.
- Chen w. s., MMed*, C H Wong, MBBS*, L Cillekens, M.App.Sc**. 2002. "Dengue Antibodies in a Suburban Community in Malaysia." *Med J Malaysia* 58(1).
- Conway, Michael J., Tonya M. Colpitts and Erol Fikrig. 2014. "Role of the Vector in Arbovirus Transmission." *Annual Review of Virology* 1(1):71-88. doi: 10.1146/annurev-virology-031413-085513.
- de Azeredo, E. L., R. Q. Monteiro and L. M. de-Oliveira Pinto. 2015. "Thrombocytopenia in Dengue: Interrelationship between Virus and the

Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators."*Mediators Inflamm* 2015:313842. doi: 10.1155/2015/313842.

De Paula, Sérgio Oliveira and Benedito Antônio Lopes da Fonseca. 2004. "*Dengue: A Review of the Laboratory Tests a Clinician Must Know to Achieve a Correct Diagnosis.*"*Brazilian Journal of Infectious Diseases* 8:390-98.

Del Angel, Rosa and Jorge Valle. 2013. *Dengue Vaccines: Strongly Sought but Not a Reality Just Yet*, Vol. 9.

Dejnirattisai, W., A. Jumnainsong, N. Onsirisakul, P. Fitton, S. Vasanawathana, W. Limpitkul, C. Puttikhunt, C. Edwards, T. Duangchinda, S. Supasa, K. Chawansuntati, P. Malasit, J. Mongkolsapaya and G. Scream. 2010. "*Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans.*"*Science* 328 (5979):745-8. doi: 10.1126/science.1185181.

Dhanoa, A., S. S. Hassan, N. K. Jahan, D. D. Reidpath, Q. K. Fatt, M. P. Ahmad, C. Y. Meng, L. W. Ming, A. Z. Zain, M. E. Phipps, I. Othman, A. B. Rabu, R. Sirajudeen, Aaba Fatan, F. A. Ghafar, H. B. Ahmad and P. Allotey. 2018. "*Seroprevalence of Dengue among Healthy Adults in a Rural Community in Southern Malaysia: A Pilot Study.*"*Infect Dis Poverty* 7(1):1. doi: 10.1186/s40249-017-0384-1.

Dhar-Chowdhury, Parnali, Kishor Kumar Paul, C. Emdad Haque, Shakhawat Hossain, L. Robbin Lindsay, Antonia Dibernardo, W. Abdullah Brooks and Michael A. Drebolt. 2017b. "*Dengue Seroprevalence, Seroconversion and Risk Factors in Dhaka, Bangladesh.*"*PLoS Negl Trop Dis* 11(3):e0005475. doi: 10.1371/journal.pntd.0005475.

Dieng, H., R. G. Saifur, A. A. Hassan, M. R. Salmah, M. Boots, T. Satho, Z. Jaal and S. AbuBakar. 2010. "*Indoor-Breeding of Aedes Albopictus in Northern Peninsular Malaysia and Its Potential Epidemiological Implications.*"*PLoS One* 5(7):e11790. doi: 10.1371/journal.pone.0011790.

Ding, C. H., Z. Z. Rashid, M. M. Rahman, N. Khang, W. N. Low, N. Hussin, M. I. Marzuki, A. N. Jaafar, N. A. Roslan and T. Chandrasekaran. 2016. "*Seroprevalence of Acute Dengue in a Malaysian Tertiary Medical Centre.*"*Pak J Med Sci* 32(2):495-8. doi: 10.12669/pjms.322.9320.

Go, Yun, Udeni Balasuriya and Chong-Kyo Lee. 2014. *Zoonotic Encephalitides Caused by Arboviruses: Transmission and Epidemiology of Alphaviruses and Flaviviruses*, Vol. 3.

Harif Nurdianah F., Zainoodin S.A. Kader, Sanmukh R. Joshi, and Norazah M. Yusof. 2014. "*Seropositive Status of Dengue Virus Infection among Blood Donors in North Malaysia.*"*Asian J Transfus Science Jan-Jun;* 8(1): 64. doi: 10.4103/0973-6247.126702.

Higa, Y. 2011. "*Dengue Vectors and Their Spatial Distribution.*"*Trop Med Health* 39 (4 Suppl):17-27. doi: 10.2149/tmh.2011-S04.

- Imai, Natsuko and Neil M. Ferguson. 2018. "Targeting Vaccinations for the Licensed Dengue Vaccine: Considerations for Serosurvey Design." PLOS ONE 13(6):e0199450. doi: 10.1371/journal.pone.0199450.
- Conway, J., Michael, Tonya Colpitts and Erol Fikrig. 2014. *Role of the Vector in Arbovirus Transmission*, Vol. 1.
- Kaur, P. and G. Kaur. 2014. "Transfusion Support in Patients with Dengue Fever." *Int J Appl Basic Med Res* 4(Suppl 1):S8-S12. doi: 10.4103/2229-516X.140708.
- Lam, S.K. 1993. "Two Decades of Dengue in Malaysia." *Tropical Medicene* 35(4):195-200.
- Lee, K. S., S. Lo, S. S. Tan, R. Chua, L. K. Tan, H. Xu and L. C. Ng. 2012. "Dengue Virus Surveillance in Singapore Reveals High Viral Diversity through Multiple Introductions and in Situ Evolution." *Infect Genet Evol* 12(1):77-85. doi: 10.1016/j.meegid.2011.10.012.
- Lescar, J. and S. Lok. 2014. "The Structural Biology of Dengue Virus." 365-76. doi: 10.1079/9781845939649.0365.
- Liang, G., X. Gao and E. A. Gould. 2015. "Factors Responsible for the Emergence of Arboviruses; Strategies, Challenges and Limitations for Their Control." *Emerg Microbes Infect* 4(3):e18. doi: 10.1038/emi.2015.18.
- Low, S. L., S. Lam, W. Y. Wong, D. Teo, L. C. Ng and L. K. Tan. 2015. "Dengue Seroprevalence of Healthy Adults in Singapore: Serosurvey among Blood Donors, 2009." *Am J Trop Med Hyg* 93(1):40-5. doi: 10.4269/ajtmh.14-0671.
- Luo, S., W. Cui, C. Li, F. Ling, T. Fu, Q. Liu, J. Ren and J. Sun. 2018. "Seroprevalence of Dengue IgG Antibodies in Symptomatic and Asymptomatic Individuals Three Years after an Outbreak in Zhejiang Province, China." *BMC Infect Dis* 18(1):92. doi: 10.1186/s12879-018-3000-5.
- Mahmood, Shahid, Hiba Nabeel, Saadia Hafeez, Urooj Zahra and Hammad Nazeer. 2013. "Seroprevalence of Dengue IgG Antibodies among Healthy Adult Population in Lahore, Pakistan." *ISRN Tropical Medicine* 2013:1-6. doi: 10.1155/2013/521396.
- MOH .2017. "History and Epidemiology of Dengue." <http://denggi.myhealth.gov.my/history-and-epidemiology-of-dengue/?lang=en>. Access date 29 September 2017.
- Malladi, S. V., R. Paul, N. Chandra, N. M. Rao and S. Y. Raju. 2013. "Ta-Gvhd, a Fatal Complication Following Blood Transfusion from a First-Degree Relative." *J Obstet Gynaecol India* 63(5):344-6. doi: 10.1007/s13224-012-0189-x.
- Mallhi, T. H., A. H. Khan, A. S. Adnan, A. Sarriff, Y. H. Khan and F. Jummaat. 2015. "Clinico-Laboratory Spectrum of Dengue Viral Infection and Risk Factors Associated with Dengue Hemorrhagic Fever: A Retrospective Study." *BMC Infect Dis* 15:399. doi: 10.1186/s12879-015-1141-3.

- Mandavdhare, Harshal and Vishal Sharma. 2016. "Differentiating Primary and Secondary Dengue Infections: Why and How?". Medical Journal of Dr. D.Y. Patil University 9(5):594-95. doi: 10.4103/0975-2870.192145.
- Mansfield, K. L., L. M. Hernandez-Triana, A. C. Banyard, A. R. Fooks and N. Johnson. 2017. "Japanese Encephalitis Virus Infection, Diagnosis and Control in Domestic Animals." *Vet Microbiol* 201:85-92. doi: 10.1016/j.vetmic.2017.01.014.
- MOH. 2015. "Management of Dengue Infection in Adults (Third Edition)."
- Mohamed Ismail, N. A., W. E. Wan Abd Rahim, S. A. Salleh, H. M. Neoh, R. Jamal and M. A. Jamil. 2014. "Seropositivity of Dengue Antibodies During Pregnancy." *ScientificWorldJournal* 2014:436975. doi: 10.1155/2014/436975.
- Mohd-Zaki, A. H., J. Brett, E. Ismail and M. L'Azou. 2014. "Epidemiology of Dengue Disease in Malaysia (2000-2012): A Systematic Literature Review." *PLoS Negl Trop Dis* 8(11):e3159. doi: 10.1371/journal.pntd.0003159.
- Mohd Zim, M. A., I. C. Sam, S. F. Omar, Y. F. Chan, S. AbuBakar and A. Kamarulzaman. 2013. "Chikungunya Infection in Malaysia: Comparison with Dengue Infection in Adults and Predictors of Persistent Arthralgia." *J Clin Virol* 56(2):141-5. doi: 10.1016/j.jcv.2012.10.019.
- Mudin, Rose Nani. 2015. "Dengue Incidence and the Prevention and Control Program in Malaysia." *The International Medical Journal Malaysia* 14(1).
- Muhammad Hanafiah J, Hayati KS, Cheng CM, Pyang GS, Nur Hayati AS, and Zaidatul Syeila ZA. 2015. "Risk Behaviour Associated with Dengue Fever among Rural Population in Malaysia." *International Journal of Public Health and Clinical Sciences* 2(1).
- Muhammad Azami, N. A., S. A. Salleh, H. M. Neoh, S. Z. Syed Zakaria and R. Jamal. 2011. "Dengue Epidemic in Malaysia: Not a Predominantly Urban Disease Anymore." *BMC Res Notes* 4:216. doi: 10.1186/1756-0500-4-216.
- Mustafa, M. S., V. Rasotgi, S. Jain and V. Gupta. 2015. "Discovery of Fifth Serotype of Dengue Virus (DENV-5): A New Public Health Dilemma in Dengue Control." *Med J Armed Forces India* 71(1):67-70. doi: 10.1016/j.mjafi.2014.09.011.
- Ng, L. C., Y. K. Chem, C. Koo, R. N. Mudin, F. M. Amin, K. S. Lee and C. C. Kheong. 2015. "2013 Dengue Outbreaks in Singapore and Malaysia Caused by Different Viral Strains." *Am J Trop Med Hyg* 92(6):1150-5. doi: 10.4269/ajtmh.14-0588.
- Normile, Dennis. 2013. *Surprising New Dengue Virus Throws a Spanner in Disease Control Efforts*, Vol. 342.

- Olivero, R. M., D. H. Hamer, W. B. MacLeod, C. M. Benoit, C. Sanchez-Vegas, E. S. Jentes, L. H. Chen, M. E. Wilson, N. Marano, E. A. Yanni, W. W. Ooi, A. W. Karchmer, L. Kogelman and E. D. Barnett. 2016. "Dengue Virus Seroconversion in Travelers to Dengue-Endemic Areas." *Am J Trop Med Hyg* 95(5):1130-36. doi: 10.4269/ajtmh.16-0159.
- Pal, Subhamoy, Allison L. Dauner, Indrani Mitra, Brett M. Forshey, Paquita Garcia, Amy C. Morrison, Eric S. Halsey, Tadeusz J. Kochel and Shuenn-Jue L. Wu. 2014. "Evaluation of Dengue Ns1 Antigen Rapid Tests and Elisa Kits Using Clinical Samples." *PLOS ONE* 9(11):e113411. doi: 10.1371/journal.pone.0113411.
- Pang, E. L. and H. S. Loh. 2016. "Current Perspectives on Dengue Episode in Malaysia." *Asian Pac J Trop Med* 9(4):395-401. doi: 10.1016/j.apjtm.2016.03.004.
- Patankar, Manisha, Bhaumik Patel, Vicky Gandhi, Parevee Shah and Mahendra Vegad. 2014. *Seroprevalence of Dengue in Gujarat, Western India: A Study at a Tertiary Care Hospital*, Vol. 3.
- Perng, Guey Chuen, Huan-Yao Lei, Yee-Shin Lin and Kulkanya Chokephaibulkit. 2011. "Dengue Vaccines: Challenge and Confrontation." *World Journal of Vaccines* 01(04):109-30. doi: 10.4236/wjv.2011.14012.
- Rafique, I., M. A. N. Saqib, M. A. Munir, H. Qureshi, I. U. Taseer, R. Iqbal, W. Ahmed, T. Akhtar and Rizwanullah. 2017. "Asymptomatic Dengue Infection in Adults of Major Cities of Pakistan." *Asian Pac J Trop Med* 10(10):1002-06. doi: 10.1016/j.apjtm.2017.09.013.
- Ranjan, P., V. Natarajan, M. Bajpai and E. Gupta. 2016. "High Seroprevalence of Dengue Virus Infection in Blood Donors from Delhi: A Single Centre Study." *J Clin Diagn Res* 10(10):DC08-DC10. doi: 10.7860/JCDR/2016/21262.8711.
- Rather, I. A., H. A. Parray, J. B. Lone, W. K. Paek, J. Lim, V. K. Bajpai and Y. H. Park. 2017. "Prevention and Control Strategies to Counter Dengue Virus Infection." *Front Cell Infect Microbiol* 7:336. doi: 10.3389/fcimb.2017.00336.
- Rosario Capeding, Maria, Huu Tran, Sri Hadinegoro, Hussain Imam Hj Muhammad Ismail, Tawee Chotpitayasunondh, Mary Noreen Chua, Chan Quang Luong, Kusnandi Rusmil, Dewa Nyoman Wirawan, Revathy Nallusamy, Punnee Pititutthithum, Usa Thisyakorn, In-Kyu Yoon, Diane van der vliet, Edith Langevin, Thelma Laot, Yanee Hutagalung, Carina Frago, Mark Boaz and Alain Bouckenoghe. 2014. *Clinical Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children in Asia: A Phase 3, Randomised, Observer-Masked, Placebo-Controlled Trial*, Vol. 384.
- Rothman, A. L. 2011. "Immunity to Dengue Virus: A Tale of Original Antigenic Sin and Tropical Cytokine Storms." *Nat Rev Immunol* 11(8):532-43. doi: 10.1038/nri3014.

- Sejvar, James J. 2003. "West Nile Virus: An Historical Overview." *The Ochsner Journal* 5(3):6-10.
- Shaharuddin, Nor. 2016. *The Trend in Dengue Incidence and Seroprevalence in Hospital Melaka, Malaysia in 2014-2015.*
- Shu, P. Y. and J. H. Huang. 2004. "Current Advances in Dengue Diagnosis." *Clin Diagn Lab Immunol* 11(4):642-50. doi: 10.1128/CDLI.11.4.642-650.2004.
- Simmons, C. P., K. McPherson, N. Van Vinh Chau, D. T. Hoai Tam, P. Young, J. Mackenzie and B. Wills. 2015. "Recent Advances in Dengue Pathogenesis and Clinical Management." *Vaccine* 33(50):7061-8. doi: 10.1016/j.vaccine.2015.09.103.
- Tauqeer Hussain Mallhi, 1, 1 Amer Hayat Khan, 1 Azmi Sarriff, 2 Azreen Syazril Adnan and Yusra Habib Khan. 2017. "Determinants of Mortality and Prolonged Hospital Stay among Dengue Patients Attending Tertiary Care Hospital: A Cross-Sectional Retrospective Analysis." *BMJ Open* bmjopen-2017-016805. doi: 7:e016805. doi:10.1136.
- Tiong, Vunjia, Juraina Abd-Jamil, H. A. Mohamed Zan, R. S. Abu-Bakar, C. L. Ew, F. L. Jafar, S. Nellis, Rosmadi Fauzi and Sazaly Abu Bakar. 2015. *Evaluation of Land Cover and Prevalence of Dengue in Malaysia*, Vol. 32.
- Tran, T. N., P. J. de Vries, L. P. Hoang, G. T. Phan, H. Q. Le, B. Q. Tran, C. M. Vo, N. V. Nguyen, P. A. Kager, N. Nagelkerke and J. Groen. 2006. "Enzyme-Linked Immunoassay for Dengue Virus IgM and IgG Antibodies in Serum and Filter Paper Blood." *BMC Infect Dis* 6:13. doi: 10.1186/1471-2334-6-13.
- Tricou, V., H. T. Vu, N. V. Quynh, C. V. Nguyen, H. T. Tran, J. Farrar, B. Wills and C. P. Simmons. 2010. "Comparison of Two Dengue Ns1 Rapid Tests for Sensitivity, Specificity and Relationship to Viraemia and Antibody Responses." *BMC Infect Dis* 10:142. doi: 10.1186/1471-2334-10-142.
- Vairo, Francesco, Emanuele Nicastri, Silvia Meschi, Monica Sane Schepisi, Maria Paglia, Nazario Bevilacqua, Sabina Mangi, Maria Rosaria Sciarrone, Roberta Chiappini, Jape Mohamed, Vincenzo Racalbuto, Antonino Di Caro, Maria R. Capobianchi and Giuseppe Ippolito. 2011. *Seroprevalence of Dengue Infection: A Cross-Sectional Survey in Mainland Tanzania and on Pemba Island, Zanzibar*, Vol. 16.
- Vasilakis, Nikos, Jane Cardosa, Kathryn Hanley, Edward Holmes and Scott Weaver. 2011. *Fever from the Forest: Prospects for the Continued Emergence of Sylvatic Dengue Virus and Its Impact on Public Health*, Vol. 9.
- Velasco-Salas, Z. I., G. M. Sierra, D. M. Guzman, J. Zambrano, D. Vivas, G. Comach, J. C. Wilschut and A. Tami. 2014. "Dengue Seroprevalence and Risk Factors for Past and Recent Viral Transmission in Venezuela: A Comprehensive Community-Based Study." *Am J Trop Med Hyg* 91(5):1039-48. doi: 10.4269/ajtmh.14-0127.

- Villar, L., G. H. Dayan, J. L. Arredondo-Garcia, D. M. Rivera, R. Cunha, C. Deseda, H. Reynales, M. S. Costa, J. O. Morales-Ramirez, G. Carrasquilla, L. C. Rey, R. Dietze, K. Luz, E. Rivas, M. C. Miranda Montoya, M. Cortes Supelano, B. Zambrano, E. Langevin, M. Boaz, N. Tornieporth, M. Saville, F. Noriega and C. Y. D. Study Group. 2015. *"Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America."* N Engl J Med 372(2):113-23. doi: 10.1056/NEJMoa1411037.
- Wang, S. M. and S. D. Sekaran. 2010. *"Early Diagnosis of Dengue Infection Using a Commercial Dengue Duo Rapid Test Kit for the Detection of Ns1, IgM, and IgG."* Am J Trop Med Hyg 83(3):690-5. doi: 10.4269/ajtmh.2010.10-0117.
- WHO. 1997. *"Dengue Hemorrhagic Fever Diagnostic, Treatment, Prevention and Control, 2nd Edition"* World Health Organization,
- WHO. 2011. "Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever" World Health Organization, 60. ISBN 978-92-9022-387-0
- WHO. 2012. *"Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases : A Roadmap for Implementation."* World Health Organization, Regional Office for South-East Asia.
- WHO. 2012. *"Dengue, Countries or area at risks, 2011* World Health Organization, <http://www.humanosphere.org/wpcontent/uploads/2013/08/DengueRiskGlobal.png>
- WHO. 2016. updates fact sheet on Dengue and Severe Dengue (29 July 2016). World Health Organization,
- WHO. 2017. *"Dengue and Severe Dengue."* (Updated April 2017). World Health Organization,
- WHO. 2017. *"Informing vaccination programs: A Guide to the Design and Conduct of Dengue Serosurvey."* World Health Organization,
- Wilder-Smith, A., L. H. Chen, E. Massad and M. E. Wilson. 2009. *"Threat of Dengue to Blood Safety in Dengue-Endemic Countries."* Emerg Infect Dis 15(1):8-11. doi: 10.3201/eid1501.071097.
- Wong, L. P., S. AbuBakar and K. Chinna. 2014. *"Community Knowledge, Health Beliefs, Practices and Experiences Related to Dengue Fever and Its Association with IgG Seropositivity."* PLoS Negl Trop Dis 8(5):e2789. doi: 10.1371/journal.pntd.0002789.
- Yamashiro T, Disla M, Petit A, Taveras D, Castro-Bello M, Lora-Orste M, Vardez S, Cesin AJ, Garcia B, Nishizono A. 2004. *"Seroprevalence of IgG Specific for Dengue Virus among Adults and Children in Santo Domingo, Dominican Republic."* Am J Trop Med Hyg 71(2):138-43.